Clinical and neurobiological characterisation of muscarinic receptor-deficit schizophrenia (MRDS)
Completed
- Conditions
- 10039628MRDSpsychosis
- Registration Number
- NL-OMON41528
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Patients with first-episode psychosis as defined by the standardised criteria of the CASH
-Medication free
-Duration of untreated psychosis no more than 1 year.
-18 years and older
Exclusion Criteria
-Use of antipsychotics and anticholinergics
-Contraindications for MRI
-Severe neurological, endocrine or psychiatric disorders
-Pregnancy
-Current use of recreational drugs; participants must be abstinent of recreational drugs such as cannabis at least 4 weaks prior to participation.
-Tardive dyskinesia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>-M1 receptor binding: ROI*s will be the hippocampus and the dorsolateral<br /><br>prefrontal cortex.</p><br>
- Secondary Outcome Measures
Name Time Method <p>-BOLD signal activation during cognitive tasks PAL (40) and ER -40 (62) under<br /><br>cholinergic challenge and in placebo. (ROI*s DLPFC and the hippocampus).<br /><br>-Neuropsychological tests: CANTAB battery for schizophrenia.<br /><br><br /><br>Additional study parameters:<br /><br>-DTI, RSfMRI, MRS<br /><br>-(Epi)genetics</p><br>